Evaluation of efficacy and safety of intralesional bleomycin in the treatment of common warts: Results of a pilot study
| Autor: | Vikas Sharma, Pushpinder S Chauhan, Shailja Chauhan, Karan Inder Singh Mehta, Vikram K Mahajan, Ritu Rawat |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Pain Pilot Projects Periungual skin Dermatology Eschar Injections Intralesional Bleomycin Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Patient satisfaction Recurrence human papilloma virus warts medicine lcsh:Dermatology Humans Adverse effect Common warts Aged Aged 80 and over Antibiotics Antineoplastic Cumulative dose business.industry Middle Aged lcsh:RL1-803 medicine.disease Injection Site Reaction Infectious Diseases chemistry Injection site pain 030220 oncology & carcinogenesis Female medicine.symptom business verrucae |
| Zdroj: | Indian Journal of Dermatology, Venereology and Leprology, Vol 85, Iss 4, Pp 397-404 (2019) |
| ISSN: | 0973-3922 0378-6323 |
| Popis: | Background: This study evaluated the efficacy and safety of intralesional bleomycin in the treatment of common warts in 50 (32 men, 18 women) patients aged between 14 and 80 (mean ± SD, 28.5 ± 13.27) years. Methods: The warts were present over dorsal hands, feet, palms, soles and periungual skin for 1 month to 10 years. They were infiltrated with bleomycin (1 mg/ml) till blanching. The total cumulative dose did not exceed 2 mg in one session. The treatment was repeated after paring of eschar at 2 weeks in case there was no or partial response. The patients were reviewed at 4, 12 and 24 weeks for cure, adverse effects or recurrences and outcome satisfaction levels. Results: Complete cure without recurrence occurred in 40 (80%) patients and partial response occurred in 7 (14%) patients at the end of the 24-week study period. Three patients did not complete follow-up. No major systemic or local adverse effects other than injection site pain for 2–3 days were noted. All cured patients were very satisfied (Likert scale 5). Conclusion: Intralesional bleomycin appears to be an effective and safe treatment for common warts including palmoplantar and periungual warts. It carries the advantage of low dose, no significant adverse effects and high patient satisfaction. Small number of patients, lack of a control group, comparing different bleomycin concentrations and a short follow-up are a few limitations of this study. Better designed studies are warranted for this useful treatment modality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|